Luteolin (123) acts as an anti-metastatic agent by inhibiting the production of MMP-9 and MMP-2, while luteoloside (90) regulates the expression of MMP-2 in human oral squamous cell carcinoma, including FaDu, HSC-3, and CA9-22, and inhibits cell migration and invasion. Here, MMP2 is linked to oral cavity squamous cell carcinoma.